Loading clinical trials...

Treatment Of Dupuytren's Contracture With Collagenase Clostridium Histolyticum Injection (Xiapex) | Clinical Trials | Clareo Health

COMPLETEDPHASE3

Treatment Of Dupuytren's Contracture With Collagenase Clostridium Histolyticum Injection (Xiapex)

Prospective Open-Label Investigation Of The Non-surgical Treatment With Collagenase Clostridium Histolyticum (Xiapex)

NCT01229436•Pfizer

View on ClinicalTrials.gov

Summary

This study will evaluate the impact of Xiapex treatment on the range of motion (ROM) of the affected fingers and the patient and physician reported treatment satisfaction and disease severity and their relation to ROM. Recovery to normal activities, recovery time (How long overall, time to use hand, time to return to work or daily activities, amount of work or daily activity time missed or reduced and affects on productivity and daily activities) will be assessed via patient diary. Use of concomitant analgesic medications will be recorded and total healthcare resource utilization (HCRU).

Eligibility

Age

18 - 70 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Presenting with a Dupuytren's contracture of at least 20 degrees caused by a palpable cord in at least one finger other than the thumb.
•Positive "table top test" defined as the inability to simultaneously place the affected finger(s) and palm flat against a table top.

Exclusion Criteria

•Received a treatment on the selected joint, within 90 days of enrollment in the study, for Dupuytren's contracture including needle aponeurotomy or any surgical procedure
•On anticoagulant medication or has received anticoagulant medication (except aspirin less than 150 mg daily) within 7 days before the first injection
•Has a chronic muscular, neurological, or neuromuscular disorder that affects the hands

Locations (28)

Pfizer Investigational Site

Copenhagen, Denmark

Pfizer Investigational Site

Silkeborg, Denmark

Pfizer Investigational Site

Montpellier, France

Pfizer Investigational Site

Nice, France

Pfizer Investigational Site

Paris, France

Pfizer Investigational Site

Paris, France

Pfizer Investigational Site

Bad Neustadt an der Saale, Germany

Pfizer Investigational Site

Berlin, Germany

Pfizer Investigational Site

Bonn, Germany

Pfizer Investigational Site

Münster, Germany

Key Dates

Start Date

December 1, 2010

Primary Completion Date

October 1, 2012

Completion Date

October 1, 2012

Last Updated

March 17, 2014

Enrollment

254

ACTUAL participants

Conditions

Dupuytren's Contracture

Interventions

Xiapex

DRUG

Real-World Data Study to Understand Participant Treatment Outcomes for Dupuytren's Contracture

NCT05877066

Dupuytren's Contracture

View study

COMPLETED

Ultrasound B Mode Imaging and Elastography

NCT04607187

Dupuytren's Contractures

View study

COMPLETEDPHASE3

Collagenase Option for Reduction of Dupuytren's Contracture in Japan

NCT01588353

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 17, 2014Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Treatment Of Dupuytren's Contracture With Collagenase Clostridium Histolyticum Injection (Xiapex)

Inclusion Criteria

Exclusion Criteria

Real-World Data Study to Understand Participant Treatment Outcomes for Dupuytren's Contracture

Ultrasound B Mode Imaging and Elastography

Collagenase Option for Reduction of Dupuytren's Contracture in Japan

Efficacy and Safety of Xiaflex Injection for Treatment of Dupuytren's Contracture of the Thumb

Phase II Randomized Study of Collagenase in Patients With Residual Type Dupuytren's Disease

Phase III Randomized Study of Collagenase in Patients With Residual Stage Dupuytren's Disease